RX 5902

Drug Profile

RX 5902

Alternative Names: RX-5902; Supinoxin

Latest Information Update: 04 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Korea Research Institute of Chemical Technology
  • Developer Rexahn Pharmaceuticals
  • Class Antineoplastics; Piperazines; Quinoxalines; Small molecules
  • Mechanism of Action RNA helicase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Breast cancer
  • Phase I Solid tumours
  • Preclinical Pancreatic cancer; Renal cell carcinoma

Most Recent Events

  • 31 Aug 2017 Rexahn Pharmaceuticals completes a phase I trial in Solid tumours (Second-line therapy or greater, Late-stage disease, Metastatic disease) in USA
  • 30 Aug 2017 Rexahn Pharmaceuticals has patent protection for RX 5902 in USA
  • 27 Feb 2017 Rexahn Pharmaceuticals completes enrolment in a phase I trial in Solid tumours in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top